$24.88
1.87% today
Nasdaq, Aug 26, 07:19 pm CET
ISIN
US60770K1079
Symbol
MRNA

Moderna Stock price

$25.35
-8.80 25.77% 1M
-7.93 23.83% 6M
-16.23 39.03% YTD
-56.31 68.96% 1Y
-116.70 82.15% 3Y
-40.90 61.74% 5Y
+6.75 36.29% 10Y
+6.75 36.29% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-1.77 6.53%
ISIN
US60770K1079
Symbol
MRNA
Industry

Key metrics

Basic
Market capitalization
$9.9b
Enterprise Value
$4.8b
Net debt
positive
Cash
$5.1b
Shares outstanding
389.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.2 | 5.0
EV/Sales
1.6 | 2.4
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
77.1%
Return on Equity
-32.7%
ROCE
-26.7%
ROIC
-43.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $2.0b
EBITDA
$-2.6b | $-4.0b
EBIT
$-2.8b | $-4.2b
Net Income
$-2.9b | $-3.9b
Free Cash Flow
$-3.5b
Growth (TTM | estimate)
Revenue
-39.1% | -39.2%
EBITDA
31.5% | -23.2%
EBIT
35.1% | -21.9%
Net Income
50.5% | -9.0%
Free Cash Flow
12.0%
Margin (TTM | estimate)
Gross
68.3%
EBITDA
-83.8% | -204.3%
EBIT
-90.5%
Net
-94.3% | -197.3%
Free Cash Flow
-113.7%
More
EPS
$-7.5
FCF per Share
$-9.0
Short interest
22.4%
Employees
6k
Rev per Employee
$560.0k
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Moderna forecast:

4x Buy
13%
20x Hold
65%
7x Sell
23%

Analyst Opinions

31 Analysts have issued a Moderna forecast:

Buy
13%
Hold
65%
Sell
23%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,078 3,078
39% 39%
100%
- Direct Costs 975 975
68% 68%
32%
2,103 2,103
4% 4%
68%
- Selling and Administrative Expenses 1,074 1,074
26% 26%
35%
- Research and Development Expense 3,815 3,815
21% 21%
124%
-2,578 -2,578
31% 31%
-84%
- Depreciation and Amortization 208 208
61% 61%
7%
EBIT (Operating Income) EBIT -2,786 -2,786
35% 35%
-91%
Net Profit -2,903 -2,903
51% 51%
-94%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Positive
Kiplinger
one day ago
Analysts say these S&P 500 stocks have at least 30% price upside over the next year or so.
Neutral
Accesswire
4 days ago
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna is on track to deliver the updated vaccine in time fo...
Neutral
Accesswire
5 days ago
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ET Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30am ET A live webcast of each of these presenta...
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today